Review
doi: 10.1007/s101560050043.
Prospects for development of new antimycobacterial drugs
Affiliations
- PMID: 11810525
- DOI: 10.1007/s101560050043
Item in Clipboard
Review
Prospects for development of new antimycobacterial drugs
J Infect Chemother.
2000 Mar.
Abstract
In this article, I have thoroughly reviewed the status of development of new antimycobacterial drugs, particularly fluoroquinolones (ciprofloxacin, ofloxacin, sparfloxacin, levofloxacin, gatifloxacin, sitafloxacin, and moxifloxacin), new macrolides (clarithromycin, azithromycin, and roxithromycin), rifamycin derivatives (rifabutin, rifapentine, and KRM-1648), and others. The main purpose of this review was to describe the in-vitro and in-vivo activities of these drugs against Mycobacterium tuberculosis and Mycobacterium avium complex. In addition, the therapeutic efficacy of these drugs in the clinical treatment of mycobacterial infections has also been briefly mentioned.
Similar articles
-
Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.Arch Immunol Ther Exp (Warsz). 2000;48(3):183-8. Arch Immunol Ther Exp (Warsz). 2000. PMID: 10912623 Review.
-
[Prospects for development of new antituberculous drugs].Kekkaku. 2002 Aug;77(8):573-84. Kekkaku. 2002. PMID: 12235850 Japanese.
-
New trends in development of antimycobacterial compounds.Infect Disord Drug Targets. 2006 Jun;6(2):159-72. doi: 10.2174/187152606784112173. Infect Disord Drug Targets. 2006. PMID: 16789877 Review.
-
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.Antimicrob Agents Chemother. 2000 Feb;44(2):283-6. doi: 10.1128/AAC.44.2.283-286.2000. Antimicrob Agents Chemother. 2000. PMID: 10639351 Free PMC article.
-
Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.Int J Antimicrob Agents. 2000 Sep;16(1):25-9. doi: 10.1016/s0924-8579(00)00163-1. Int J Antimicrob Agents. 2000. PMID: 11185410
Cited by
-
Molecular modeling and in silico characterization of Mycobacterium tuberculosis TlyA: possible misannotation of this tubercle bacilli-hemolysin.BMC Struct Biol. 2011 Mar 28;11:16. doi: 10.1186/1472-6807-11-16. BMC Struct Biol. 2011. PMID: 21443791 Free PMC article.
-
Recent Biochemical Advances in Antitubercular Drugs: Challenges and Future.Curr Top Med Chem. 2024;24(21):1829-1855. doi: 10.2174/0115680266286294240610102911. Curr Top Med Chem. 2024. PMID: 38919089 Review.
-
Inhibitory effect of NO-releasing ciprofloxacin (NCX 976) on Mycobacterium tuberculosis survival.Antimicrob Agents Chemother. 2003 Jul;47(7):2299-302. doi: 10.1128/AAC.47.7.2299-2302.2003. Antimicrob Agents Chemother. 2003. PMID: 12821482 Free PMC article.
-
In vitro activity of ciprofloxacin, ofloxacin and levofloxacin against Mycobacterium tuberculosis.Ann Saudi Med. 2005 Sep-Oct;25(5):409-12. doi: 10.5144/0256-4947.2005.409. Ann Saudi Med. 2005. PMID: 16270765 Free PMC article.
-
Mycobacterium avium-intracellulare contamination of mammalian cell cultures.In Vitro Cell Dev Biol Anim. 2009 Jan-Feb;45(1-2):75-90. doi: 10.1007/s11626-008-9143-8. Epub 2008 Oct 15. In Vitro Cell Dev Biol Anim. 2009. PMID: 18855078
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
